Adaptive biotechnologies corporation (ADPT)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19
Operating activities
Net loss

-81,623

-68,606

0

0

0

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation expense

6,290

6,100

0

0

0

Noncash lease expense

0

-

-

-

-

Share-based compensation expense

14,753

13,124

0

0

0

Intangible assets amortization

1,703

1,698

0

0

0

Investment amortization

4,401

4,463

0

0

0

Fair value adjustment of convertible preferred stock warrant

-

2,266

0

0

0

Benefit from income tax

0

-

-

-

-

Other

0

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

5,280

7,817

0

0

0

Inventory

2,663

1,231

0

0

0

Prepaid expenses and other current assets

1,318

8,576

0

0

0

Accounts payable and accrued liabilities

1,923

6,149

0

0

0

Deferred rent

-

78

0

0

0

Operating lease liabilities

0

-

-

-

-

Deferred revenue

-36,079

266,927

0

0

0

Other

0

-

-

-

-

Net cash (used in) provided by operating activities

-104,505

205,404

0

0

0

Investing activities
Purchases of property and equipment

10,332

11,200

0

0

0

Purchases of marketable securities

721,104

884,217

0

0

0

Proceeds from sales and maturities of marketable securities

614,674

413,720

0

0

0

Net cash provided by (used in) investing activities

-116,762

-481,697

0

0

0

Financing activities
Proceeds from exercise of stock options

8,925

4,055

0

0

0

Other

-

-12

0

0

0

Net cash provided by financing activities

324,751

319,916

0

0

0

Net increase in cash, cash equivalents and restricted cash

103,484

43,623

0

0

0

Noncash investing and financing activities
Purchases of equipment included in accounts payable and accrued liabilities

977

773

0

0

0

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

0

0

Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases

0

-

-

-

-